releasing hormone


Also found in: Dictionary, Thesaurus, Financial, Encyclopedia, Wikipedia.

re·leas·ing fac·tors (RF),

1. any substance, usually of hypothalamic origin, capable of accelerating the rate of secretion of a given hormone by the anterior pituitary gland;
2. factors required in the termination phase of either RNA biosynthesis or protein biosynthesis. Synonym(s): termination factor
3. colloquial shortened form for the HMG-CoA reductase inhibitors used as antihyperlipidemic agents, whose generic names end with the suffix statin. Synonym(s): statins
Synonym(s): liberins, releasing hormone

releasing hormone (RH)

one of several peptides produced by the hypothalamus and secreted directly into the anterior pituitary gland via a connecting vein. Each of the releasing hormones stimulates the pituitary to secrete a specific tropic hormone. Thus corticotropic-releasing hormone stimulates the pituitary to secrete adrenocorticotropic hormone, whereas growth hormone-releasing hormone stimulates the secretion of growth hormone. Previously called releasing factor.

re·leas·ing fac·tors

(rĕ-lēs'ing fak'tŏrz)
1. Substances, usually of hypothalamic origin, capable of accelerating the rate of secretion of a given hormone by the anterior pituitary gland.
2. Factors required in the termination phase of either RNA biosynthesis or protein biosynthesis.
Synonym(s): liberins, releasing hormone.

releasing hormone

Abbreviation: RH
Any of a group of substances secreted by the hypothalamus that control or inhibit the release of various hormones. They include thyrotropin-releasing hormone, gonadotropin-releasing hormone, dopamine, growth hormone-releasing hormone, corticotropin-releasing hormone, and somatostatin. Dopamine and somatostatin act to inhibit release of the hormones they act upon.
See also: hormone
Mentioned in ?
References in periodicals archive ?
0 p-values according to the [chi]2 test for categorical data (*) Student's t-test for normally distributed data or the Mann-Whitney U test for non-normally distributed quantitative data Values were means [+ or -] standard deviation and medians for non-normally distributed quantitative data GnRHa: Gonadotropin releasing hormone agonist, n: Number, y: Year, d: Day, IU: International units, hCG: Human chorionic gonadotropin, OPU: Oocyte pick-up, MII: Metaphase II, IVF: In vitro fertilization Table 2.
Outcome of intracytoplasmic sperm injection after preinstillation of a gonadotropin releasing hormone agonist in the uterine cavity just before embryo transfer/Embriyo transferi oncesi uterin kaviteye gonadotropin serbestlestirici hormon agonisti enjeksiyonunun intrasitoplazmik sperm enjeksiyonu sonuclari
Gonadotropin releasing hormone analogue repairs reduced endometrial cell apoptosis in endometriosis in vitro.
The anticancer activity compared between triptorelin and a new gonadotropin releasing hormone analogue
Response to challenge with gonadotropin releasing hormone agonist in amother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor a clinical research center study.
Single nucleotide polymorphisms of the GnRHR gene associated with reproductive traits of Japanese flounder (Paralichthys olivaceus)
5 mg is the new sustained-release six-month formulation of a gonatropin- releasing hormone (GnRH) agonist analogue developed by Debiopharm Group.
Ipsen launches Decapeptyl 6-Month Formulation (LP 22.5 mg) in France
Progenta's effects on shrinking fibroids were at least equivalent to that observed in women using an approved gonadotropin releasing hormone agonist ("GnRHa"), which is the most effective drug intervention for the condition.
Zonagen, Inc. Receives Notification of Issuance of U.S. Patent on Progenta
Without a comprehensive NCD, as requested by the Company and reflected in this draft decision memorandum, Plenaxis(R) could receive inconsistent coverage among the Medicare carriers and intermediaries who may fail to distinguish this drug, the first gonadotropin releasing hormone (GnRH) antagonist approved for the treatment of advanced prostate cancer, from luteinizing hormone releasing hormone (LHRH) agonists.
PRAECIS PHARMACEUTICALS INCORPORATED Announces Issuance of Draft National Coverage Determination for Plenaxis
The study was initiated to compare the performance of AEZS-130 against the then-available diagnostic growth hormone releasing hormone (GHRH) + Arginine (ARG) standard test.
Aeterna Zentaris reports AEZS-130 interim Phase III data analysis
They were randomized into one of five parallel groups; placebo, three different dose levels of Progenta(TM), and a positive control group consisting of Lucrin(R), an approved gonadotropin releasing hormone agonist ("GnRHa").
Zonagen Reports Interim Assessment of One Month Data from Study of Progenta in the Treatment of Uterine Fibroids
The conclusions made by the ASCO expert panel on androgen deprivation therapy (ADT) is that the use of nonsteroidal anti-androgens can be looked at as an alternative to orchiectomy or drug treatment with luteinizing hormone releasing hormone agonists (medical castration).
Research and Markets: Analytical Tool: Prostate Cancer, The Ultimate Tool to Analyse The Future Competitive Situation of Prostate Cancer Therapeutics
They have been randomized into one of five parallel groups; placebo, three different doses of Progenta(TM), and a positive control group consisting of Lupron(R), an approved gonadotropin releasing hormone agonist ("GnRHa").
Zonagen Provides Update for European Study of Progenta in Women with Uterine Fibroids
They will be randomized into one of five parallel groups; placebo, three different doses of Progenta(TM), and a positive control group consisting of an approved gonadotropin releasing hormone agonist (GnRHa).
Zonagen to Commence European Study of Progenta in Women with Uterine Fibroids
1 YOU'RE FEELING TIRED 'Stress has a physiological effect on your body, by releasing hormones into your bloodstream that accelerate your heart rate and breathing,' explains Tim.
Five signs your stress is out of control; It's International Stress Awareness Day on 1 November. With 11.7 million working days a year lost to stress in the UK, we asked Tim Hipgrave, Emotional Health Expert at Nuffield Health, to talk us through the signs that you might be stressed without even realising it - and just what we can do to calm down

Medical browser ?
Full browser ?